

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Vyvanse (lisdexamfetamine dimesylate)

Override(s)	Approval Duration
Prior Authorization	1 year

APPROVAL CRITERIA

Requests for Vyvanse (lisdexamfetamine dimesylate) may be approved if the following criteria is met:

- I. Individual is 6 years of age or older; **AND**
 - II. Individual has a diagnosis of attention deficit hyperactivity disorder (ADHD);
- AND**
- III. Individual has had an appropriate trial of **one** of the following:
 - A. Methylphenidate extended-release; **OR**
 - B. Extended-release amphetamine/dextroamphetamine salt combination; **OR**
 - IV. Individual has been diagnosed with coexisting ADHD and substance use disorder;
- OR**
- V. Individual is 18 years of age or older; **AND**
 - VI. Individual has a diagnosis of binge-eating disorder.

Requests for Vyvanse (lisdexamfetamine dimesylate) may not be approved for the following:

- I. Weight loss

Note:

Attention deficit hyperactivity disorder (ADHD) may also be referred to as attention deficit disorder (ADD).

Vyvanse (lisdexamfetamine) has black box warnings for abuse and dependence. CNS stimulants have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Key References:

CRX-ALL-0532-20

PAGE 1 OF 2 03/15/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 26, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics*. 2011; 128:1007-1022. Available from: <http://pediatrics.aappublications.org/content/128/5/1007.full.pdf>. Accessed: June 26, 2019.
6. Charach A, Dashti B, Carson P, et al. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Comparative Effectiveness Review No. 44. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. MME2202 290-02-0020.) AHRQ Publication No. 12-EHC003-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2011. Last Review July 2012. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed: June 26, 2019.
7. Post RE and Kurlansik SL. Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults. *Am Fam Physician*. 2012; 85(9):890-896. Available from: <http://www.aafp.org/afp/2012/0501/p890.html>. Accessed June 26, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.